Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …

The incidence of type 2 diabetes (T2D) has been increasing worldwide, and diabetic kidney
disease (DKD) remains one of the leading long-term complications of T2D. Several lines of …

Mitophagy preserves microvascular structure and function during myocardial
ischemia/reperfusion (I/R) injury. Empagliflozin, an anti-diabetes drug, may also protect …

Background Empagliflozin has been reported to protect endothelial cell function, regardless
of diabetes status. However, the role of empagliflozin in microvascular protection during …

Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …

Cardiovascular disease is the leading cause of morbidity and mortality in diabetes. Recent
clinical studies indicate that sodium-glucose co-transporter 2 (SGLT2) inhibitors improve …

Heart failure (HF) is marked by distinctive changes in myocardial uptake and utilization of
energy substrates. Among the different types of HF, HF with preserved ejection fraction …

Type 2 diabetes mellitus (T2DM) is a known independent risk factor for atherosclerotic
cardiovascular disease (CVD) and solid epidemiological evidence points to heart failure …

Background Metabolic syndrome and related metabolic disturbances represent a state of
low-grade inflammation, which accelerates insulin resistance, type 2 diabetes (T2D) and …

Cardiorenal syndrome encompasses a spectrum of disorders involving heart and kidney
dysfunction, and sharing common risk factors, such as hypertension and diabetes. Clinical …